An mRNA-based therapeutic cancer vaccine receives full FDA approval for curative intent before 2032.
Therapeutic vaccines are in late-stage clinical trials for multiple solid tumors. Resolution requires standard FDA approval for an mRNA cancer treatment with curative indication.
Across 6 frontier models answering independently, the panel leans no: the median is 35%.
They do not agree: Grok puts it at 52% and Claude at 12%, 40 points apart. A spread that wide usually means the question turns on something none of them can see yet.
Nothing is settled until 22 Oct 2036, when the outcome is checked against sources and every number above gets a permanent score.
What each one said
-
GrokxAI
Phase 3 success plus full BLA for a personalized mRNA neoantigen vaccine in adjuvant melanoma.
- Moderna/Merck INTerpath-001 (mRNA-4157+pembro) primary completion ~2029; a positive readout could support 2030-31 full approval.
- Cancer vaccines historically fail at high rates, yet PD-1 combo plus individualized neoantigens already showed Phase 2b DFS benefit, lifting this case.
- Interim OS/DFS win or BioNTech parallel program succeeding would raise odds; a failed Phase 3 would drop them near zero.
52% -
GeminiGoogle
Turns on whether adjuvant trials like INTerpath-001 replicate Phase 2 recurrence-free survival gains and secure full standard BLA.
- Merck and Moderna's mRNA-4157 Phase 3 completes around 2028-2029, leaving a narrow 2-3 year window to achieve full non-accelerated approval.
- FDA labels strictly specify adjuvant or recurrence-free survival endpoints, creating semantic risk for explicit curative designation.
- Historical Phase 3 oncology trial failure rates hover around 40-50%, though strong Phase 2 data pushes this slightly above baseline.
43% -
QwenAlibaba
Turns on whether Moderna/Merck's INTerpath-001 Phase 3 in adjuvant melanoma reads out positive and files before 2030.
- mRNA-4157 Phase 2 showed 44% RFS improvement in resected melanoma, but oncology Phase 3 success rates hover near 50% even after strong Phase 2 signals.
- If Phase 3 data lands mid-2028 and BLA files by early 2029, priority review could yield approval by late 2029—tight but feasible before 2032.
- A shift to metastatic-only indications or a requirement for longer follow-up would push approval past the window; adjuvant setting is the clearest curative-intent path.
37% -
GPTOpenAI
It hinges on whether a late-stage mRNA vaccine can show durable survival benefit sufficient for a curative label, not just recurrence delay.
- FDA will require a completed pivotal trial, BLA review, and convincing long-term outcomes before the October 2036 cutoff.
- The closest programs, notably Moderna/Merck's V940 with pembrolizumab, are promising but have not established cure-level survival evidence.
- Cancer vaccines have a long history of encouraging early signals failing in phase 3; a positive mature melanoma readout would raise this sharply.
32% -
DeepSeekDeepSeek
Whether Moderna/Merck's mRNA-4157 (V940) adjuvant melanoma data hold up and convert a BLA into full approval before 2032.
- The lead asset is mRNA-4157 plus Keytruda in adjuvant melanoma; Phase 3 INTerpath-001 reads out around 2027-2029, so a BLA could land 2029-2031.
- FDA has never approved an mRNA cancer therapeutic; the only mRNA approvals are COVID vaccines, and no therapeutic cancer vaccine has ever cleared full approval.
- Curative intent is the binding constraint: adjuvant melanoma is the closest fit, but regulators may grant accelerated approval first, which would not satisfy this…
22% -
ClaudeAnthropic
Hinges on Moderna/Merck's V940 (melanoma) Phase 3 (INTerpath-001/017) readouts and whether FDA grants full approval with curative framing by 2032.
- Lead candidate mrna-4157/V940 is in Phase 3 for melanoma/NSCLC with readouts expected mid-decade, but full approval (not accelerated) typically needs years of follow-up…
- Historical base rate for any single oncology therapeutic reaching full FDA approval within this tight window from current trial stage is low, even for promising…
- Curative intent framing is unusual for FDA labels (most are adjuvant/recurrence-reduction), so exact resolution criteria may not be met even if approved.
12%
6 of 6 models answered · 40 points between the highest and lowest. None was shown the market price.
Question sourced from a news sweep on 25 Oct 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.